Award winning market research company Fact.MR’s ongoing bilateral osteoarthritis treatment market study forecasts a largely positive outlook for 2021, as novel therapeutic advancements lead to new treatment approaches. Long-term prospects until 2031 appear promising, with key developments in cartilage, subchondral bone, inflammation reduction, pain process and metabolic syndrome management respectively.
According to Fact.MR, key bilateral osteoarthritis drug manufacturers are banking on a slew of drug therapy approvals sanctioned by regulatory authorities. For instance, in 2019, the US Food & Drug Administration introduced a slew of approvals targeting specific diseases, including bilateral osteoarthritis, paving way for the availability of the Voltaren Arthritis Pain diclofenac sodium topical gel 1% in early 2020 via the prescription-to-OTC channel.
Frontiers are opening up with respect to Regenokine treatment. Currently approved for deployment across Germany, the therapeutic approach is yet to receive FDA approval for full-fledged use across the United States. Akin to platelet rich plasma therapy, the approach helps promote regeneration of muscles and cartilage. Current conclusions suggest that almost 75% of people with mild-stage knee osteoarthritis are expected to benefit from this treatment.
“Accelerating efforts for developing breakthroughs in bilateral osteoarthritis treatment is prompting manufacturers to develop new oral and injectable drugs along with other non-invasive therapeutic approaches, bolstering growth prospects,” says a Fact.MR analyst.
Request a report sample pdf – https://www.factmr.com/connectus/sample?flag=B&rep_id=2895
Key Takeaways from Fact.MR’s Bilateral Osteoarthritis Treatment Market Study
- By treatment type, corticosteroids are anticipated to register enhanced usage, attributed to swift relief from joint inflammation
- Demand for injectable drugs to acquire center stage, oral drugs to remain popular
- US to drive majority of bilateral osteoarthritis drug sales amid high incidence of knee osteoarthritis
- High reliance on aspirin and ibuprofen drugs to steer UK bilateral osteoarthritis treatment market growth
- Germany to experience a nudge amid recent approval of the Regenokine anti-inflammatory treatment for joint pain
- Burgeoning research on incorporating hyaluronic acid injections to drive French market growth
- India to receive major tailwinds, attributed to the presence of over two out of five bilateral osteoarthritis patients
Bilateral Osteoarthritis Treatment Market- Prominent Drivers
- Development of low-dose corticosteroids and non-steroidal anti-inflammatory drugs to stimulate market growth
- Breakthroughs in discovering new treatment approaches, such as chondroitin sulfate based medicines, is likely to augment future growth
- Government initiatives, such as the US Consumer Assistance Programs (CAPs), are helping to fund increased osteoarthritis treatment
Bilateral Osteoarthritis Treatment Market- Key Restraints
- Cartilage damage resulting out of excessive reliance on corticosteroids to hamper bilateral osteoarthritis drug sales
- Persisting evidence to practice gaps due to inconsistencies between theory and practice of numerous therapeutic approaches is restraining penetration
Discover more about the bilateral osteoarthritis treatment market with figures, data tables and the table of contents. You will also find detailed market segmentation on
https://www.factmr.com/report/2895/bilateral-osteoarthritis-treatment-market
Competitive Landscape
Johnson & Johnson Services (DePuy Synthes), Novartis AG, GlaxoSmithKline Plc., Abbott Laboratories, Zimmer Biomet Holdings Inc., Pfizer Inc., Amgen Plc., F-Hoffmann-La Roche Ltd., Biogen Inc. and Eli Lily & Co. are some prominent bilateral osteoarthritis treatment providers operating in the market. Besides these, numerous regional level players also exist across key geographies.
Certain manufacturers are emphasizing on completing a definitive sales target to augment their market presence. For instance, DePuy Synthes reported that as of June 2020, it’s ATTUNE® Knee cement-less system was utilized by over a million patients worldwide, highlighting the product’s surging popularity since its release in 2019.
Additionally, players also emphasize on strategic acquisitions. In December 2020, Zimmer Biomet Holdings Inc., completed the acquisition of A&E Medical Corporation, with the objective of expanding its portfolio of sternal closure devices. The expansion is likely to expand Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic (CMET) business line.
Get Customization on this Report for Specific Research Solutions
https://www.factmr.com/connectus/sample?flag=RC&rep_id=2895
More Insights on the Global Bilateral Osteoarthritis Market
In its latest report, Fact.MR offers unbiased analysis of the global bilateral osteoarthritis market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of treatment type (analgesics, NSAIDs, corticosteroids and hyaluronic acid), route of administration (oral & injectable) and distribution channel (hospital pharmacies, retail pharmacies, drug stores and e-commerce) across seven regions (North America, Latin America, Western Europe, CIS & Russia, Japan, APEJ and Middle East & Africa)
Explore Fact.MR’s Coverage on the Healthcare Domain:
Leukocyte Count Testing Market – According to the latest research by Fact.MR, the leukocyte count testing market is set to witness exponential growth with over 7%-8% CAGR during 2021-2031. Increasing bacterial infection with the growing adoption of point of care devices will witness a promising growth outlook for leukocyte count testing in the long run.
At-Home Celiac Testing Market – According to the Latest Research by the Fact.MR The Celiac Testing market is set to gain growth in the forecast period 2021-2031 at a CAGR of 8.0%. The Reason for the growth is The increase in prevalence of Celiac disease globally.
Polysaccharide Hemostatic System Market – According to the latest research by Fact.MR, Polysaccharide Hemostatic System market is set to witness an XX% growth during the year 2021-2031.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
